TLDR Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
Significant advances in understanding vitiligo have led to new treatments, such as ruxolitinib cream, though it often fails to achieve complete repigmentation, especially on hands and feet. Surgical approaches, like melanocyte grafts, are proposed for stable vitiligo but have low success rates. A study found that the absence of initial CD8+ T cell infiltrates in vitiligo lesions predicts better surgical outcomes. This suggests that assessing CD8+ T cell levels before surgery could identify good candidates for grafting. Combining surgery with immunomodulating agents may improve outcomes for lesions with CD8+ T cell infiltrates. Prospective trials are needed to confirm these findings and optimize treatment strategies.
New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.
1 citations,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
9 citations,
December 2017 in “The Journal of Allergy and Clinical Immunology” New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
